Tricyclic compounds and use thereof

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
Novel tricyclic compounds with selective S1PR1 agonistic activity address the limitations of current S1PR1 agonists, providing effective treatment for multiple sclerosis and other autoimmune diseases.

US12637448B2Active Publication Date: 2026-05-26NANCHANG HELIOEAST PHARMA +1

View PDF 13 Cites 0 Cited by

Patent Information

Authority / Receiving Office: US · United States
Patent Type: Patents(United States)
Current Assignee / Owner: NANCHANG HELIOEAST PHARMA
Filing Date: 2021-03-02
Publication Date: 2026-05-26

Application Information

Patent Timeline

02 Mar 2021

Application

26 May 2026

Publication

US12637448B2

IPC: C07D413/14; C07D401/14; C07D417/14

CPC: C07D413/14; C07D401/14; C07D417/14; A61P37/00

AI Tagging

Application Domain

Organic chemistry Immunological disorders

Technology Topics

Pharmaceutical medicine Medicinal chemistry

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Smart Images

Figure US12637448-C00001
Figure US12637448-C00002
Figure US12637448-C00003

Patent Text Reader

Abstract

Disclosed in the present invention are a series of tricyclic compounds, and particularly disclosed are a compound shown in formula (I) or a pharmaceutically acceptable salt thereof.

Need to check novelty before this filing date? Find Prior Art